Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

The Almond Yogurt Study (AYS) (AYS)

16 novembre 2026 mis à jour par: Amanda Wright, Ph.D., University of Guelph

The Impact of Almond Food Structure in a Standardized Yogurt Breakfast Meal on Gastric Emptying, Oral Processing Behaviours, Appetite-Regulating Hormones, Postprandial Metabolism, and Subjective Satiety: A Randomized Crossover Trial

The goal of this clinical trial is to explore how almond food structure influences gastric emptying rates when consumed by healthy adult women as part of a standardized breakfast meal. The main questions it aims to answer are:

  • Does the structure of almonds (whole, chopped, buttered) influence gastric emptying ?
  • What is the correlation between chewing behaviour, gastric emptying, and changes in postprandial triacylglycerols and satiety (hormones and ratings) within the context of an increasingly disrupted nut matrix.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

This study is investigating how the structure of almonds (whole, chopped, buttered) as part of a yogurt-based breakfast meal influences gastric emptying and postprandial metabolism. Over three randomized visits, fasted healthy adult female participants will arrive at the research centre where an iv-catheter will be inserted for serial blood sampling over 6 hours for analysis of plasma triacylglycerols, GLP-1, CCK, glucose, and insulin. Participants will consume each meal while being video recorded to quantify chewing frequency and eating time. Paper questionnaires will periodically assess participants' eating experiences and hunger sensations throughout the visit (e.g., exertion, liking, hunger, fullness). Gastric ultrasonography will be used to visualize and quantify the cross-sectional area of the gastric antrum so that changes in gastric volume can be tracked over time. Overall, this study aims to determine how almond form, as an example of food structure, influences chewing, gastric emptying, satiety and postprandial metabolism.

Type d'étude

Interventionnel

Inscription (Estimé)

25

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Ontario
      • Guelph, Ontario, Canada, N1G 2G4
        • Department of Human Health Sciences
        • Contact:
        • Contact:
          • Alison M Duncan, PhD
        • Chercheur principal:
          • Amanda J Wright, PhD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 45 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  • Healthy female adults aged 18-45 years.
  • Body Mass Index (BMI) between 18.5-27.9 kg/m2, or waist circumference of less than 88 cm
  • Visible gastric antrum on ultrasound
  • No known food allergies or sensitivities
  • Non restrained eaters (TFEQ, see below)
  • No history of gastrointestinal diseases that may interfere with eating behavior or digestion
  • Not on medications that affect appetite (including GLP-1 agonists), digestion, blood sugar regulation, saliva production, or chewing
  • Stable medication use
  • Non-smokers
  • Not gained or lost significant weight during the past 3 months
  • Regular monthly menstrual cycles
  • Not pregnant, lactating or post-menopausal

Exclusion Criteria:

  • Diabetes or other metabolic disorders affecting glycemia and overall cardiometabolic health
  • Blood pressure > 140/90 mm Hg
  • Any food allergies, intolerances, or sensitivities
  • Pregnant or breastfeeding
  • Participation in another clinical trial
  • Excessive alcohol consumption (more than 14 drinks per week)
  • Smokers or those with a smoking history of more than 10 years
  • Regular use of recreational drugs (e.g., marijuana, ecstasy, LSD, magic mushrooms, etc.)
  • Restrained eater (>16) as defined by the questionnaire at screening (Three-Factor Eating Questionnaire, Stunkard et al., 1985)
  • Unusual sleep patterns
  • Irregular breakfast consumption
  • Recent weight changes, or intended weight loss or gain; lost/gained 10% of body weight within the last 6 months
  • Food allergies/sensitivities or any life-threatening allergies
  • Using medications known to affect appetite, digestion, blood sugar regulation, or chewing/swallowing (excluding oral contraceptives).
  • Experiences dry mouth in general or due to medication side effects
  • Inability to adhere to study protocols
  • Not comfortable providing IV-line blood samples
  • Not comfortable providing ultrasound scans
  • Not comfortable being video recorded while eating
  • Avoids consuming almonds/yogurt in general
  • Avoids eating hard foods to prevent dental fractures

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Whole - Chopped - Buttered

Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, chopped almonds at the second intervention visit, and almonds processed into almond butter at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Expérimental: Whole - Buttered - Chopped

Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, buttered almonds at the second intervention visit, and chopped almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Expérimental: Buttered - Whole - Chopped

Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, whole almonds at the second intervention visit, and chopped almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Expérimental: Buttered - Chopped - Whole

Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, chopped almonds at the second intervention visit, and whole almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Expérimental: Chopped - Buttered - Whole

Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, buttered almonds at the second intervention visit, and whole almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Expérimental: Chopped - Whole - Buttered

Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, whole almonds at the second intervention visit, and buttered almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Gastric emptying half-time
Délai: At each study visit, based on assessments at 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated from ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after consumption of the breakfast meal, in minutes

At each study visit, based on assessments at 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Eating time
Délai: From 0 minutes until the end of eating the breakfast meal

The time to consume the breakfast meal based on video recordings, in minutes

From 0 minutes until the end of eating the breakfast meal
Changes from baseline in postprandial satiety visual analogue scale ratings
Délai: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Paper questionnaire scale ratings (in mm) of Hunger, Fullness, Prospective Consumption, and Desire to Eat where each is 100 mm ranging from 0 (minimum) to 100 (maximum). For example, 0 = Not at all Hungry and 100 = As Hungry as Possible.

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma triacylglycerol concentration
Délai: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in mmol/L

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Triacylglycerol response - incremental area under the curve (AUC)
Délai: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma GLP-1 concentration
Délai: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pg/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
GLP-1 response - incremental area under the curve (AUC)
Délai: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma CCK concentration
Délai: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pmol/L

0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
CCK response - incremental area under the curve (AUC)
Délai: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in gastric volume
Délai: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal, in mL

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Gastric volume - incremental area under the curve (AUC)
Délai: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Borg rating of perceived exertion
Délai: Immediately after the breakfast meal is consumed

Participant paper scale rating of effort required to chew the breakfast meal where 0 = No effort at all and 10 = Very very severe chewing effort

Immediately after the breakfast meal is consumed
Changes from baseline in plasma blood glucose concentration
Délai: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in mmol/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Glucose response - incremental area under the curve (AUC)
Délai: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma blood insulin concentration
Délai: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pmol/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Insulin response - Area under the curve (AUC)
Délai: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Product liking and perceived attributes
Délai: Immediately after eating the breakfast meal

Participant paper scale questionnaire ratings

Immediately after eating the breakfast meal
Eating rate
Délai: From 0 minutes until the end of eating the breakfast meal

Calculated from video recordings of eating session, combining meal portion consumed (in grams) and eating time (minutes), grams/minute

From 0 minutes until the end of eating the breakfast meal
Number of chews
Délai: From 0 minutes until the end of eating the breakfast meal

Determined by count from video recordings of each eating session

From 0 minutes until the end of eating the breakfast meal

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

15 novembre 2026

Achèvement primaire (Estimé)

15 décembre 2027

Achèvement de l'étude (Estimé)

19 décembre 2027

Dates d'inscription aux études

Première soumission

29 octobre 2026

Première soumission répondant aux critères de contrôle qualité

16 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • ID3014
  • 400819 (Autre subvention/numéro de financement: Natural Sciences & Engineering Research Council of Canada)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Description du régime IPD

Although we are not required to make this data available, we are currently working to understand how to do this in a safe way, as per our institutional guidelines. As we learn more, we may pursue this. We are obtaining consent from study participants for this option.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .